Advair Diskus is a combination inhaled corticosteroid and long-acting beta2-adrenergic agonist (ICS/LABA) indicated for the maintenance treatment of asthma in patients aged 4 years and older and for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is designed to reduce inflammation and bronchoconstriction simultaneously, offering a comprehensive approach to managing obstructive airway diseases. This medication is not indicated for the relief of acute bronchospasm and should be used consistently as prescribed for optimal disease control.

Features

• Contains fluticasone propionate (corticosteroid) and salmeterol (long-acting bronchodilator)
• Delivered via a unique Diskus inhalation device
• Available in multiple strength combinations (e.g., 100/50, 250/50, 500/50 mcg)
• Pre-metered, breath-actuated dosing
• Does not require shaking or priming
• Dose counter to track remaining inhalations

Benefits

• Provides dual therapy targeting both inflammation and bronchoconstriction
• Reduces frequency and severity of asthma exacerbations
• Improves lung function (FEV1) in asthma and COPD patients
• Enhances overall quality of life through better symptom control
• Convenient twice-daily dosing regimen
• May reduce need for rescue inhaler use

Common use

Advair Diskus is commonly prescribed for the maintenance treatment of asthma in patients who require both an inhaled corticosteroid and a long-acting bronchodilator to achieve adequate control. It is also used for the maintenance treatment of COPD in patients with a history of exacerbations. The medication is typically part of a comprehensive management plan that may include patient education, environmental control measures, and monitoring of pulmonary function.

Dosage and direction

For asthma treatment in patients 4 years and older: The recommended starting dosage is based on disease severity and prior therapy. Typical adult dosage is 1 inhalation twice daily (approximately 12 hours apart). For COPD: 1 inhalation of Advair Diskus 250/50 twice daily. Patients must rinse their mouth without swallowing after inhalation to reduce the risk of oropharyngeal candidiasis. Do not exceed recommended dosage. The Diskus device should never be washed and must be kept dry.

Precautions

Advair Diskus may increase the risk of asthma-related death. Not for use in treating acute symptoms. Patients should have a short-acting beta2-agonist for rescue therapy. Caution required in patients with cardiovascular disorders, convulsive disorders, thyrotoxicosis, diabetes, or ketoacidosis. May cause systemic corticosteroid effects at higher doses. Monitor patients for changes in bone mineral density, ocular effects (cataracts, glaucoma), and growth velocity in pediatric patients. Paradoxical bronchospasm may occur.

Contraindications

Hypersensitivity to fluticasone propionate, salmeterol, or any component of the formulation. Not for use as primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required. Contraindicated in patients with severe hypersensitivity to milk proteins.

Possible side effects

Common side effects include upper respiratory tract infection, throat irritation, hoarseness, headache, oral candidiasis, and cough. More serious side effects may include pneumonia (in COPD patients), cardiovascular effects (tachycardia, palpitations), increased blood pressure, paradoxical bronchospasm, immunosuppression, hypercorticism, adrenal suppression, and reduced bone mineral density. Allergic reactions including anaphylaxis, angioedema, rash, and urticaria may occur.

Drug interaction

Concomitant use with strong CYP3A4 inhibitors (ketoconazole, ritonavir) may increase systemic exposure to salmeterol and increase risk of cardiovascular effects. Use with other beta-adrenergic agents may potentiate sympathetic effects. Caution with monoamine oxidase inhibitors and tricyclic antidepressants. Corticosteroid effects may be enhanced in patients receiving other systemic corticosteroids.

Missed dose

Take the next dose at the regular time. Do not double the dose to make up for a missed one. Maintain the regular dosing schedule to ensure consistent therapeutic effect.

Overdose

Overdose may produce symptoms of excessive beta-adrenergic stimulation including tachycardia, arrhythmias, tremor, headache, and metabolic effects. Corticosteroid overdose may cause hypercorticism. Treatment should be supportive and symptomatic. Cardiac monitoring is recommended. Consider discontinuation of therapy and implement appropriate supportive measures.

Storage

Store at room temperature between 68°F-77°F (20°C-25°C) in a dry place away from direct heat or sunlight. Keep in the original foil pouch until ready for use. Discard 1 month after opening the foil pouch or when the counter reads “0,” whichever comes first. Do not store in bathroom areas where moisture may affect the medication. Keep out of reach of children and pets.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Advair Diskus should be used only under the supervision of a qualified healthcare provider. Patients should not adjust dosage or discontinue medication without consulting their physician. Individual results may vary based on patient-specific factors and disease severity.

Reviews

Clinical studies demonstrate Advair Diskus significantly improves lung function and quality of life measures compared to monotherapy components. In asthma trials, patients experienced fewer exacerbations and improved symptom control. COPD studies showed reduced exacerbation frequency and improved health status. Many patients report better daily symptom control and reduced rescue medication use. However, some users note the importance of proper inhalation technique for optimal results and report occasional throat irritation or hoarseness.